New options for testing and treating some of the most common sexually transmitted diseases are becoming available.

For much of the past year, the UK’s medicines pricing debate has cast a long shadow over the life sciences sector. The deadlock over NHS rebates – and the uncertainty surrounding the successor to VPAG ...